Eddit
Zeile 14: | Zeile 14: | ||
{{tp|p=32169119|t=2020. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak ? an update on the status |pdf=|usr=}} | {{tp|p=32169119|t=2020. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak ? an update on the status |pdf=|usr=}} | ||
{{tp|p=32297723|t=2020. COVID-2019: update on epidemiology, disease spread and management |pdf=|usr=}} | {{tp|p=32297723|t=2020. COVID-2019: update on epidemiology, disease spread and management |pdf=|usr=}} | ||
+ | {{tp|p=32188753|t=2020. COVID-19: Knowns, Unknowns, and Questions |pdf=|usr=}} | ||
+ | {{tp|p=32109013|t=ä. Clinical Characteristics of Coronavirus Disease 2019 in China |pdf=|usr=}} | ||
+ | {{tp|p=31978945|t=2020. A Novel Coronavirus from Patients with Pneumonia in China, 2019 |pdf=|usr=}} | ||
+ | |||
+ | |||
Zeile 34: | Zeile 39: | ||
{{tp|p=32165386|t=2020. Complete Genome Sequence of a 2019 Novel Coronavirus (SARS-CoV-2) Strain Isolated in Nepal |pdf=|usr=}} | {{tp|p=32165386|t=2020. Complete Genome Sequence of a 2019 Novel Coronavirus (SARS-CoV-2) Strain Isolated in Nepal |pdf=|usr=}} | ||
{{ttp|p=32289821|t=ä. Extreme genomic CpG deficiency in SARS-CoV-2 and evasion of host antiviral defense |pdf=|usr=}} | {{ttp|p=32289821|t=ä. Extreme genomic CpG deficiency in SARS-CoV-2 and evasion of host antiviral defense |pdf=|usr=}} | ||
− | + | {{tp|p=32371472|t=2020. SARS-CoV-2 and ORF3a: Nonsynonymous Mutations, Functional Domains, and Viral Pathogenesis |pdf=|usr=}} | |
+ | {{tp|p=32123347|t=ä. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 |pdf=|usr=}} | ||
+ | {{tp|p=32303698|t=ä. A map of SARS-CoV-2 and host cell interactions |pdf=|usr=}} | ||
*'''[[Target binding and uptake]]''' | *'''[[Target binding and uptake]]''' | ||
{{tp|p=32199943|t=ä. Predicting the angiotensin converting enzyme 2 (ACE2) utilizing capability as the receptor of SARS-CoV-2 |pdf=|usr=}} | {{tp|p=32199943|t=ä. Predicting the angiotensin converting enzyme 2 (ACE2) utilizing capability as the receptor of SARS-CoV-2 |pdf=|usr=}} | ||
{{ttp|p=32362314|t=ä. A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells |pdf=|usr=}} | {{ttp|p=32362314|t=ä. A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells |pdf=|usr=}} | ||
+ | {{tp|p=32221306|t=2020. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV |pdf=|usr=}} | ||
+ | {{tp|p=32094589|t=ä. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses |pdf=|usr=}} | ||
*'''[[Cytopathic effects]]''' | *'''[[Cytopathic effects]]''' | ||
Zeile 57: | Zeile 66: | ||
{{ttp|p=32305501|t=ä. The Potential Role of Th17 Immune Responses in Coronavirus Immunopathology and Vaccine-induced Immune Enhancement |pdf=|usr=}} | {{ttp|p=32305501|t=ä. The Potential Role of Th17 Immune Responses in Coronavirus Immunopathology and Vaccine-induced Immune Enhancement |pdf=|usr=}} | ||
{{tp|p=32248387|t=ä. Use of DAMPs and SAMPs as Therapeutic Targets or Therapeutics: A Note of Caution |pdf=|usr=}} | {{tp|p=32248387|t=ä. Use of DAMPs and SAMPs as Therapeutic Targets or Therapeutics: A Note of Caution |pdf=|usr=}} | ||
+ | {{tp|p=32321823|t=2020. COVID-19: an Immunopathological View |pdf=|usr=}} | ||
+ | {{tp|p=32284614|t=ä. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19 |pdf=|usr=}} | ||
+ | {{tp|p=32273594|t=ä. COVID-19: immunopathology and its implications for therapy |pdf=|usr=}} | ||
+ | {{tp|p=32249845|t=ä. Fighting COVID-19 exhausts T cells |pdf=|usr=}} | ||
+ | {{tp|p=32355329|t=ä. SARS-CoV-2-reactive T cells in patients and healthy donors |pdf=|usr=}} | ||
+ | {{ttp|p=32355328|t=ä. Impaired interferon signature in severe COVID-19 |pdf=|usr=}} | ||
+ | {{tp|p=32346093|t=ä. The trinity of COVID-19: immunity, inflammation and intervention |pdf=|usr=}} | ||
+ | {{tp|p=32346091|t=ä. Neutralizing antibody response in mild COVID-19 |pdf=|usr=}} | ||
+ | {{tp|p=32303697|t=ä. Will we see protection or reinfection in COVID-19?|pdf=|usr=}} | ||
+ | {{tp|p=32303696|t=ä. Macrophages: a Trojan horse in COVID-19?|pdf=|usr=}} | ||
+ | |||
+ | |||
Zeile 62: | Zeile 83: | ||
{{tp|p=32353251|t=ä. COVID-19 cytokine storm: the interplay between inflammation and coagulation |pdf=|usr=}} | {{tp|p=32353251|t=ä. COVID-19 cytokine storm: the interplay between inflammation and coagulation |pdf=|usr=}} | ||
{{tp|p=32339596|t=ä. Predictive factors of poor outcomes in the COVID-19 epidemic: Consider the inflammatory response |pdf=|usr=}} | {{tp|p=32339596|t=ä. Predictive factors of poor outcomes in the COVID-19 epidemic: Consider the inflammatory response |pdf=|usr=}} | ||
− | + | {{tp|p=32249847|t=ä. In the eye of the COVID-19 cytokine storm |pdf=|usr=}} | |
---- | ---- | ||
Zeile 83: | Zeile 104: | ||
*'''[[Pulmonary embolism, coagulation]]''' | *'''[[Pulmonary embolism, coagulation]]''' | ||
{{tp|p=32330428|t=ä. Hospital-based use of thromboprophylaxis in patients with COVID-19 |pdf=|usr=}} | {{tp|p=32330428|t=ä. Hospital-based use of thromboprophylaxis in patients with COVID-19 |pdf=|usr=}} | ||
− | + | {{tp|p=32268022|t=ä. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19 |pdf=|usr=}} | |
*'''[[Hematology]]''' | *'''[[Hematology]]''' | ||
+ | {{tp|p=32294340|t=ä. Immune Thrombocytopenic Purpura in a Patient with Covid-19 |pdf=|usr=}} | ||
+ | |||
*'''[[Microvascular]]''' | *'''[[Microvascular]]''' | ||
Zeile 93: | Zeile 116: | ||
{{tp|p=32334650|t=ä. Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes |pdf=|usr=}} | {{tp|p=32334650|t=ä. Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes |pdf=|usr=}} | ||
{{tp|p=32360126|t=2020. Myocardial injury and COVID-19: Possible mechanisms |pdf=|usr=}} | {{tp|p=32360126|t=2020. Myocardial injury and COVID-19: Possible mechanisms |pdf=|usr=}} | ||
− | + | {{tp|p=32302081|t=ä. ST-Segment Elevation in Patients with Covid-19 ? A Case Series |pdf=|usr=}} | |
{{tp|p=32319272|t=2020. COVID-19 and cardiovascular disorder |pdf=|usr=}} | {{tp|p=32319272|t=2020. COVID-19 and cardiovascular disorder |pdf=|usr=}} | ||
{{tp|p=32340429|t=2020. The role of natriuretic peptide estimation in severe COVID-19 |pdf=|usr=}} | {{tp|p=32340429|t=2020. The role of natriuretic peptide estimation in severe COVID-19 |pdf=|usr=}} | ||
+ | {{tp|p=32348640|t=ä. Out-of-Hospital Cardiac Arrest during the Covid-19 Outbreak in Italy |pdf=|usr=}} | ||
+ | {{tp|p=32139904|t=ä. COVID-19 and the cardiovascular system |pdf=|usr=}} | ||
+ | |||
*'''[[Neurology, ophthalmology, orl]]''' | *'''[[Neurology, ophthalmology, orl]]''' | ||
{{tp|p=32305563|t=ä. Features of anosmia in COVID-19 |pdf=|usr=}} | {{tp|p=32305563|t=ä. Features of anosmia in COVID-19 |pdf=|usr=}} | ||
+ | {{tp|p=32302082|t=ä. Guillain-Barre Syndrome Associated with SARS-CoV-2 |pdf=|usr=}} | ||
+ | {{tp|p=32294339|t=ä. Neurologic Features in Severe SARS-CoV-2 Infection |pdf=|usr=}} | ||
+ | |||
*'''[[Dermatology]]''' | *'''[[Dermatology]]''' | ||
Zeile 110: | Zeile 139: | ||
*'''[[Kidney, urology]]''' | *'''[[Kidney, urology]]''' | ||
+ | {{tp|p=32273593|t=ä. Kidney involvement in COVID-19 and rationale for extracorporeal therapies |pdf=|usr=}} | ||
+ | |||
+ | |||
+ | |||
---- | ---- | ||
Zeile 116: | Zeile 149: | ||
{{tp|p=32243911|t=ä. C-reactive protein levels in the early stage of COVID-19 |pdf=|usr=}} | {{tp|p=32243911|t=ä. C-reactive protein levels in the early stage of COVID-19 |pdf=|usr=}} | ||
{{tp|p=32291399|t=ä. Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies |pdf=|usr=}} | {{tp|p=32291399|t=ä. Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies |pdf=|usr=}} | ||
+ | {{tp|p=32249846|t=ä. Dysregulation of lung myeloid cells in COVID-19 |pdf=|usr=}} | ||
+ | |||
+ | |||
*'''[[Disease Models]]''' | *'''[[Disease Models]]''' | ||
Zeile 123: | Zeile 159: | ||
{{tp|p=32341622|t=2020. SARS-CoV-2: Camazotz s Curse |pdf=|usr=}} | {{tp|p=32341622|t=2020. SARS-CoV-2: Camazotz s Curse |pdf=|usr=}} | ||
{{tp|p=32246819|t=2020. Pulmonary High-Resolution Computed Tomography (HRCT) Findings of Patients with Early-Stage Coronavirus Disease 2019 (COVID-19) in Hangzhou, China |pdf=|usr=}} | {{tp|p=32246819|t=2020. Pulmonary High-Resolution Computed Tomography (HRCT) Findings of Patients with Early-Stage Coronavirus Disease 2019 (COVID-19) in Hangzhou, China |pdf=|usr=}} | ||
− | + | {{tp|p=32358574|t=ä. 100 years of influenza research seen through the lens of Covid-19 |pdf=|usr=}} | |
Zeile 134: | Zeile 170: | ||
{{tp|p=32183357|t=2020. 2019 Novel Coronavirus Disease (COVID-19): Paving the Road for Rapid Detection and Point-of-Care Diagnostics |pdf=|usr=}} | {{tp|p=32183357|t=2020. 2019 Novel Coronavirus Disease (COVID-19): Paving the Road for Rapid Detection and Point-of-Care Diagnostics |pdf=|usr=}} | ||
{{tp|p=32106462|t=2020. Disposable DNA Amplification Chips with Integrated Low-Cost Heaters ? |pdf=|usr=}} | {{tp|p=32106462|t=2020. Disposable DNA Amplification Chips with Integrated Low-Cost Heaters ? |pdf=|usr=}} | ||
− | + | {{tp|p=32074444|t=2020. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients |pdf=|usr=}} | |
Zeile 171: | Zeile 207: | ||
{{tp|p=32271728|t=2020. Coronavirus Disease 2019 in Children - United States, February 12?April 2, 2020 |pdf=|usr=}} | {{tp|p=32271728|t=2020. Coronavirus Disease 2019 in Children - United States, February 12?April 2, 2020 |pdf=|usr=}} | ||
{{tp|p=32345328|t=2020. Analysis of the susceptibility of lung cancer patients to SARS-CoV-2 infection |pdf=|usr=}} | {{tp|p=32345328|t=2020. Analysis of the susceptibility of lung cancer patients to SARS-CoV-2 infection |pdf=|usr=}} | ||
− | + | {{tp|p=32218613|t=ä. Coronaviruserkrankung bei Kindern ? erste Daten aus Wuhan |pdf=|usr=}} | |
+ | {{ttp|p=32317808|t=ä. COVID-19 bei hospitalisierten Kindern und Jugendlichen: Ein systematischer Review zu publizierten Fallserien (Stand 31 03 2020) und erste Daten aus Deutschland |pdf=|usr=}} | ||
+ | {{tp|p=32339915|t=ä. Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19 |pdf=|usr=}} | ||
+ | {{tp|p=32315980|t=2020. COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?|pdf=|usr=}} | ||
+ | {{tp|p=32348641|t=ä. Covid-19 in Immune-Mediated Inflammatory Diseases ? Case Series from New York |pdf=|usr=}} | ||
+ | {{tp|p=32187458|t=ä. SARS-CoV-2 Infection in Children |pdf=|usr=}} | ||
+ | {{tp|p=32163697|t=2020. Detection of Covid-19 in Children in Early January 2020 in Wuhan, China |pdf=|usr=}} | ||
+ | {{tp|p=32227760|t=ä. Renin?Angiotensin?Aldosterone System Inhibitors in Patients with Covid-19 |pdf=|usr=}} | ||
+ | {{tp|p=32302077|t=ä. Clinical Characteristics of Pregnant Women with Covid-19 in Wuhan, China |pdf=|usr=}} | ||
+ | {{tp|p=32237670|t=ä. An Uncomplicated Delivery in a Patient with Covid-19 in the United States |pdf=|usr=}} | ||
+ | {{tp|p=32265531|t=ä. COVID-19 and cancer: what we know so far |pdf=|usr=}} | ||
+ | {{tp|p=32346090|t=ä. Does asthma make COVID-19 worse?|pdf=|usr=}} | ||
+ | {{tp|p=32246101|t=ä. Controversies of renin?angiotensin system inhibition during the COVID-19 pandemic |pdf=|usr=}} | ||
Zeile 179: | Zeile 227: | ||
{{tp|p=32333842|t=2020. The key role of palliative care in response to the COVID-19 tsunami of suffering |pdf=|usr=}} | {{tp|p=32333842|t=2020. The key role of palliative care in response to the COVID-19 tsunami of suffering |pdf=|usr=}} | ||
{{tp|p=32197096|t=ä. COVID-19 in pregnant women ? Authors reply |pdf=|usr=}} | {{tp|p=32197096|t=ä. COVID-19 in pregnant women ? Authors reply |pdf=|usr=}} | ||
+ | {{tp|p=32283004|t=ä. Universal Screening for SARS-CoV-2 in Women Admitted for Delivery |pdf=|usr=}} | ||
+ | {{tp|p=32346676|t=ä. Crowdsourcing a crisis response for COVID-19 in oncology |pdf=|usr=}} | ||
+ | {{tp|p=32161408|t=2020. Lack of maternal?fetal SARS-CoV-2 transmission |pdf=|usr=}} | ||
+ | {{tp|p=32284613|t=ä. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding |pdf=|usr=}} | ||
+ | {{tp|p=32231328|t=ä. Interaction between RAAS inhibitors and ACE2 in the context of COVID-19 |pdf=|usr=}} | ||
+ | {{tp|p=32327737|t=ä. Obesity and impaired metabolic health in patients with COVID-19 |pdf=|usr=}} | ||
Zeile 186: | Zeile 240: | ||
{{tp|p=32164830|t=2020. COVID-19 with spontaneous pneumomediastinum |pdf=|usr=}} | {{tp|p=32164830|t=2020. COVID-19 with spontaneous pneumomediastinum |pdf=|usr=}} | ||
{{tp|p=32229159|t=ä. SARS-CoV-2 infection presenting with hematochezia |pdf=|usr=}} | {{tp|p=32229159|t=ä. SARS-CoV-2 infection presenting with hematochezia |pdf=|usr=}} | ||
+ | {{tp|p=32004427|t=2020. First Case of 2019 Novel Coronavirus in the United States |pdf=|usr=}} | ||
+ | |||
Zeile 195: | Zeile 251: | ||
{{tp|p=32214079|t=2020. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) - United States, February 12-March 16, 2020 |pdf=|usr=}} | {{tp|p=32214079|t=2020. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) - United States, February 12-March 16, 2020 |pdf=|usr=}} | ||
{{tp|p=32290644|t=2020. Clinical and epidemiologic profile of the initial COVID-19 patients at a tertiary care centre in India |pdf=|usr=}} | {{tp|p=32290644|t=2020. Clinical and epidemiologic profile of the initial COVID-19 patients at a tertiary care centre in India |pdf=|usr=}} | ||
+ | {{tp|p=32227758|t=ä. Covid-19 in Critically Ill Patients in the Seattle Region ? Case Series |pdf=|usr=}} | ||
+ | {{tp|p=32302078|t=ä. Clinical Characteristics of Covid-19 in New York City |pdf=|usr=}} | ||
+ | |||
*'''[[Registries]]''' | *'''[[Registries]]''' | ||
Zeile 221: | Zeile 280: | ||
{{tp|p=32231349|t=2020. Chloroquine in COVID-19: the evidence |pdf=|usr=}} | {{tp|p=32231349|t=2020. Chloroquine in COVID-19: the evidence |pdf=|usr=}} | ||
{{tp|p=32231348|t=2020. Emerging prophylaxis strategies against COVID-19 |pdf=|usr=}} | {{tp|p=32231348|t=2020. Emerging prophylaxis strategies against COVID-19 |pdf=|usr=}} | ||
− | + | {{tp|p=32291351|t=2020. Repurposing Didanosine as a Potential Treatment for COVID-19 Using Single-Cell RNA Sequencing Data |pdf=|usr=}} | |
+ | {{tp|p=32187464|t=ä. A Trial of Lopinavir?Ritonavir in Adults Hospitalized with Severe Covid-19 |pdf=|usr=}} | ||
+ | {{tp|p=32187463|t=ä. Covid-19 ? The Search for Effective Therapy |pdf=|usr=}} | ||
+ | {{tp|p=32275812|t=ä. Compassionate Use of Remdesivir for Patients with Severe Covid-19 |pdf=|usr=}} | ||
+ | {{tp|p=32354113|t=2020. On Facing the SARS-CoV-2 (COVID-19) with Combination of Nanomaterials and Medicine: Possible Strategies and First Challenges |pdf=|usr=}} | ||
+ | {{tp|p=32326343|t=2020. Can Nanotechnology and Materials Science Help the Fight against SARS-CoV-2?|pdf=|usr=}} | ||
+ | {{tp|p=32366817|t=2020. A human monoclonal antibody blocking SARS-CoV-2 infection |pdf=|usr=}} | ||
+ | {{tp|p=32203437|t=ä. Insights from nanomedicine into chloroquine efficacy against COVID-19 |pdf=|usr=}} | ||
+ | {{tp|p=32358580|t=ä. COVID-19: a case for inhibiting IL-17?|pdf=|usr=}} | ||
+ | {{tp|p=32358579|t=ä. Will helminth co-infection modulate COVID-19 severity in endemic regions?|pdf=|usr=}} | ||
+ | {{tp|p=32296135|t=ä. COVID-19: risk for cytokine targeting in chronic inflammatory diseases?|pdf=|usr=}} | ||
+ | {{tp|p=32355330|t=ä. Inactivated vaccine for SARS-CoV-2 |pdf=|usr=}} | ||
+ | {{tp|p=32327719|t=ä. Complement as a target in COVID-19?|pdf=|usr=}} | ||
+ | {{tp|p=32346092|t=ä. Cancer therapy tool informs COVID-19 vaccines |pdf=|usr=}} | ||
+ | {{tp|p=32346094|t=ä. COVID-19 vaccine design: the Janus face of immune enhancement |pdf=|usr=}} | ||
+ | {{tp|p=32317716|t=ä. The potential danger of suboptimal antibody responses in COVID-19 |pdf=|usr=}} | ||
+ | *[https://www.biorxiv.org/content/10.1101/2020.03.22.002386v3 A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing] | ||
+ | {{tp|p=32286538|t=ä. Human antibodies can neutralize SARS-CoV-2 |pdf=|usr=}} | ||
Zeile 238: | Zeile 314: | ||
{{tp|p=32035510|t=2020. 2019-nCoV transmission through the ocular surface must not be ignored |pdf=|usr=}} | {{tp|p=32035510|t=2020. 2019-nCoV transmission through the ocular surface must not be ignored |pdf=|usr=}} | ||
{{tp|p=32199469|t=2020. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples |pdf=|usr=}} | {{tp|p=32199469|t=2020. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples |pdf=|usr=}} | ||
− | + | {{tp|p=32214231|t=ä. COVID-19: faecal?oral transmission?|pdf=|usr=}} | |
*'''[[Biophysics of aerosols]]''' | *'''[[Biophysics of aerosols]]''' | ||
{{tp|p=32340347|t=2020. Airborne Transmission Route of COVID-19: Why 2 Meters/6 Feet of Inter-Personal Distance Could Not Be Enough |pdf=|usr=}} | {{tp|p=32340347|t=2020. Airborne Transmission Route of COVID-19: Why 2 Meters/6 Feet of Inter-Personal Distance Could Not Be Enough |pdf=|usr=}} | ||
{{tp|p=32360356|t=ä. Putting some context to the aerosolization debate around SARS-CoV-2 |pdf=|usr=}} | {{tp|p=32360356|t=ä. Putting some context to the aerosolization debate around SARS-CoV-2 |pdf=|usr=}} | ||
− | + | {{tp|p=32294374|t=ä. Droplets and Aerosols in the Transmission of SARS-CoV-2 |pdf=|usr=}} | |
*'''[[Passive protective equipment]]''' | *'''[[Passive protective equipment]]''' | ||
Zeile 261: | Zeile 337: | ||
{{tp|p=32210421|t=2020. COVID-19 in intensive care Some necessary steps for health care workers |pdf=|usr=}} | {{tp|p=32210421|t=2020. COVID-19 in intensive care Some necessary steps for health care workers |pdf=|usr=}} | ||
{{tp|p=32297490|t=2020. COVID-19 pandemic: what consequences for cardiac rehabilitation?|pdf=|usr=}} | {{tp|p=32297490|t=2020. COVID-19 pandemic: what consequences for cardiac rehabilitation?|pdf=|usr=}} | ||
+ | {{tp|p=32278860|t=2020. Immunosuppression during the COVID-19 pandemic in neuromyelitis optica spectrum disorders patients: A new challenge |pdf=|usr=}} | ||
+ | {{tp|p=32335508|t=2020. One Aspect of Coronavirus disease (COVID-19) Outbreak in Iran: High Anxiety among MS Patients |pdf=|usr=}} | ||
+ | {{tp|p=32334820|t=2020. The COVID-19 pandemic and the use of MS disease-modifying therapies |pdf=|usr=}} | ||
+ | {{tp|p=31986242|t=2020. Medical Journals and the 2019-nCoV Outbreak |pdf=|usr=}} | ||
+ | {{tp|p=32329975|t=ä. Covid-19 and Kidney Transplantation |pdf=|usr=}} | ||
+ | {{tp|p=32242095|t=ä. Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic |pdf=|usr=}} | ||
+ | {{tp|p=32341524|t=ä. Cancer and COVID-19 ? potentially deleterious effects of delaying radiotherapy |pdf=|usr=}} | ||
+ | {{tp|p=32296166|t=ä. Provision of cancer care during the COVID-19 pandemic |pdf=|usr=}} | ||
+ | {{tp|p=32214232|t=ä. Management of IBD during the COVID-19 outbreak: resetting clinical priorities |pdf=|usr=}} | ||
+ | {{tp|p=32249840|t=ä. Minimizing the risk of COVID-19 among patients on dialysis |pdf=|usr=}} | ||
+ | |||
+ | |||
+ | |||
---- | ---- | ||
Zeile 285: | Zeile 374: | ||
*'''[[Economic aspects of the status hygienicus]]''' | *'''[[Economic aspects of the status hygienicus]]''' | ||
− | + | {{tp|p=32242087|t=ä. What the stock market tells us about the post-COVID-19 world |pdf=|usr=}} | |
Zeile 295: | Zeile 384: | ||
*'''[[Host, vector, one health, atmospheric aspects]]''' | *'''[[Host, vector, one health, atmospheric aspects]]''' | ||
{{tp|p=32236594|t=2020. Possibility of transmission through dogs being a contributing factor to the extreme Covid-19 outbreak in North Italy |pdf=|usr=}} | {{tp|p=32236594|t=2020. Possibility of transmission through dogs being a contributing factor to the extreme Covid-19 outbreak in North Italy |pdf=|usr=}} | ||
+ | {{tp|p=31996413|t=2020. Discovery of Bat Coronaviruses through Surveillance and Probe Capture-Based Next-Generation Sequencing |pdf=|usr=}} | ||
+ | {{tp|p=32051570|t=2020. Novel coronavirus takes flight from bats?|pdf=|usr=}} | ||
*'''[[Origin of Covid19]]''' | *'''[[Origin of Covid19]]''' | ||
+ | {{tp|p=32376697|t=2020. An Extensive Meta-Metagenomic Search Identifies SARS-CoV-2-Homologous Sequences in Pangolin Lung Viromes |pdf=|usr=}} | ||
+ | {{tp|p=32284615|t=ä. The proximal origin of SARS-CoV-2 |pdf=|usr=}} | ||
+ | |||
+ | |||
*'''[[Epidemiology]]''' | *'''[[Epidemiology]]''' | ||
{{tp|p=32282789|t=2020. Public Health Interventions to Mitigate Early Spread of SARS-CoV-2 in Poland |pdf=|usr=}} | {{tp|p=32282789|t=2020. Public Health Interventions to Mitigate Early Spread of SARS-CoV-2 in Poland |pdf=|usr=}} | ||
Zeile 310: | Zeile 405: | ||
{{tp|p=32324720|t=2020. Cleaning and Disinfectant Chemical Exposures and Temporal Associations with COVID-19 ? National Poison Data System, United States, January 1, 2020?March 31, 2020 |pdf=|usr=}} | {{tp|p=32324720|t=2020. Cleaning and Disinfectant Chemical Exposures and Temporal Associations with COVID-19 ? National Poison Data System, United States, January 1, 2020?March 31, 2020 |pdf=|usr=}} | ||
{{tp|p=32298247|t=2020. Characteristics of Health Care Personnel with COVID-19 - United States, February 12-April 9, 2020 |pdf=|usr=}} | {{tp|p=32298247|t=2020. Characteristics of Health Care Personnel with COVID-19 - United States, February 12-April 9, 2020 |pdf=|usr=}} | ||
+ | {{tp|p=32265315|t=2020. 2019 Novel Coronavirus (COVID-19) Pandemic: Built Environment Considerations To Reduce Transmission |pdf=|usr=}} | ||
+ | {{tp|p=32003551|t=2020. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany |pdf=|usr=}} | ||
+ | {{tp|p=31995857|t=2020. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus?Infected Pneumonia |pdf=|usr=}} | ||
+ | {{tp|p=32329972|t=ä. Asymptomatic Transmission, the Achilles? Heel of Current Strategies to Control Covid-19 |pdf=|usr=}} | ||
+ | {{tp|p=32182409|t=ä. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1 |pdf=|usr=}} | ||
+ | {{tp|p=32289214|t=ä. Spread of SARS-CoV-2 in the Icelandic Population |pdf=|usr=}} | ||
+ | *[https://www.thegatewaypundit.com/2020/05/key-stat-43-u-s-covid-19-deaths-come-0-6-population/ 130fold relativ risk in part of us population] | ||
+ | {{tp|p=32273611|t=ä. A framework for identifying regional outbreak and spread of COVID-19 from one-minute population-wide surveys |pdf=|usr=}} | ||
+ | {{tp|p=31988464|t=2020. China s response to a novel coronavirus stands in stark contrast to the 2002 SARS outbreak response |pdf=|usr=}} | ||
+ | {{tp|p=32284619|t=ä. On the responsible use of digital data to tackle the COVID-19 pandemic |pdf=|usr=}} | ||
+ | {{tp|p=32284618|t=ä. Digital technology and COVID-19 |pdf=|usr=}} | ||
+ | {{tp|p=32322102|t=ä. Modelling the COVID-19 epidemic and implementation of population-wide interventions in Italy |pdf=|usr=}} | ||
+ | *'''[[Failure of executive measures]]''' | ||
− | + | {{tp|p=32221514|t=ä. How behavioural science data helps mitigate the COVID-19 crisis |pdf=|usr=}} | |
---- | ---- | ||
*'''[[Political abuse of Covid19]]''' | *'''[[Political abuse of Covid19]]''' | ||
− | + | {{tp|p=32203324|t=ä. COVID-19 and the crisis of national development |pdf=|usr=}} | |
*'''[[Lost people]]''' | *'''[[Lost people]]''' | ||
− | + | {{tp|p=32294342|t=ä. Death from Covid-19 of 23 Health Care Workers in China |pdf=|usr=}} | |
{{tp|p=32334040|t=ä. The fate of house cats during the COVID-19 pandemic |pdf=|usr=}} | {{tp|p=32334040|t=ä. The fate of house cats during the COVID-19 pandemic |pdf=|usr=}} | ||
*'''[[Lost civilization]]''' | *'''[[Lost civilization]]''' | ||
Zeile 331: | Zeile 439: | ||
*'''[[History of covid19 exploration]]''' | *'''[[History of covid19 exploration]]''' | ||
+ | {{tp|p=C7110433|t=ä. Coronaviren: von der banalen Erkältung zum schweren Lungenversagen: Chronologie einer Pandemie |pdf=|usr=}} | ||
+ | {{tp|p=32108160|t=2020. Emergence of a novel human coronavirus threatening human health |pdf=|usr=}} | ||
+ | {{tp|p=31988490|t=2020. Outbreak of a novel coronavirus |pdf=|usr=}} | ||
+ | |||
Zeile 339: | Zeile 451: | ||
{{tp|p=32360951|t=2020. The first Ramadan during COVID-19 pandemic: 1 8 billion Muslims should fast or not?|pdf=|usr=}} | {{tp|p=32360951|t=2020. The first Ramadan during COVID-19 pandemic: 1 8 billion Muslims should fast or not?|pdf=|usr=}} | ||
{{tp|p=32368884|t=2020. Management of COVID-19: the risks associated with treatment are clear, but the benefits remain uncertain |pdf=|usr=}} | {{tp|p=32368884|t=2020. Management of COVID-19: the risks associated with treatment are clear, but the benefits remain uncertain |pdf=|usr=}} | ||
− | + | {{tp|p=C7144332|t=ä. On being human in the face of a pandemic |pdf=|usr=}} | |
*'''[[Research tools]]''' | *'''[[Research tools]]''' | ||
Zeile 345: | Zeile 457: | ||
{{tp|p=32365567|t=2020. Lab-on-a-Chip Technologies for the Single Cell Level: Separation, Analysis, and Diagnostics |pdf=|usr=}} | {{tp|p=32365567|t=2020. Lab-on-a-Chip Technologies for the Single Cell Level: Separation, Analysis, and Diagnostics |pdf=|usr=}} | ||
− | + | *'''[[PrePrint scene''' | |
+ | *[https://prelights.biologists.com/ prelights] | ||
*'''[[from the ads]]''' | *'''[[from the ads]]''' |
Version vom 28. Mai 2020, 22:04 Uhr
32311318 ä. SARS-CoV-2 and viral sepsis: observations and hypotheses
32325026 2020. Endothelial cell infection and endotheliitis in COVID-19
32363726 2020. The Novel Coronavirus - Latest Findings
32144890 2020. The Novel Coronavirus ? A Snapshot of Current Knowledge
32032682 ä. Pathogenicity and transmissibility of 2019-nCoV?A quick overview and comparison with other emerging viruses
32017984 2020. Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China
32226946 ä. COVID-19: a novel zoonotic disease caused by a coronavirus from China: what we know and what we don?t
32169119 2020. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak ? an update on the status
32297723 2020. COVID-2019: update on epidemiology, disease spread and management
32188753 2020. COVID-19: Knowns, Unknowns, and Questions
32109013 ä. Clinical Characteristics of Coronavirus Disease 2019 in China
31978945 2020. A Novel Coronavirus from Patients with Pneumonia in China, 2019
C7155395 ä. German recommendations for critically ill patients with COVID?19
32166350 ä. Empfehlungen zur intensivmedizinischen Therapie von Patienten mit COVID-19
32029004 2020. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)
32307014 2020. Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19 |
32350227 2020. Characteristics of SARS-CoV-2 isolated from asymptomatic carrier in Tokyo
32007145 2020. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding
32342926 2020. Properties of Coronavirus and SARS-CoV-2
32194253 ä. Molecular basis of COVID-19 relationships in different species: a one health perspective
32302675 ä. Comparative computational analysis of SARS-CoV-2 nucleocapsid protein epitopes in taxonomically related coronaviruses
32165386 2020. Complete Genome Sequence of a 2019 Novel Coronavirus (SARS-CoV-2) Strain Isolated in Nepal
32289821 ä. Extreme genomic CpG deficiency in SARS-CoV-2 and evasion of host antiviral defense |
32371472 2020. SARS-CoV-2 and ORF3a: Nonsynonymous Mutations, Functional Domains, and Viral Pathogenesis
32123347 ä. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2
32303698 ä. A map of SARS-CoV-2 and host cell interactions
32199943 ä. Predicting the angiotensin converting enzyme 2 (ACE2) utilizing capability as the receptor of SARS-CoV-2
32362314 ä. A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells |
32221306 2020. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
32094589 ä. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses
32304647 2020. SARS-CoV-2 shedding and infectivity
32304646 ä. SARS-CoV-2 shedding and infectivity ? Authors reply
32259560 ä. Interleukin-6 as a potential biomarker of COVID-19 progression
32092539 2020. Is COVID-19 receiving ADE from other coronaviruses? |
32268188 ä. It is too soon to attribute ADE to COVID-19
32361001 ä. Bioinformatic analysis and identification of single-stranded RNA sequences recognized by TLR7/8 in the SARS-CoV-2, SARS-CoV, and MERS-CoV genomes
32305501 ä. The Potential Role of Th17 Immune Responses in Coronavirus Immunopathology and Vaccine-induced Immune Enhancement |
32248387 ä. Use of DAMPs and SAMPs as Therapeutic Targets or Therapeutics: A Note of Caution
32321823 2020. COVID-19: an Immunopathological View
32284614 ä. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19
32273594 ä. COVID-19: immunopathology and its implications for therapy
32249845 ä. Fighting COVID-19 exhausts T cells
32355329 ä. SARS-CoV-2-reactive T cells in patients and healthy donors
32355328 ä. Impaired interferon signature in severe COVID-19 |
32346093 ä. The trinity of COVID-19: immunity, inflammation and intervention
32346091 ä. Neutralizing antibody response in mild COVID-19
32303697 ä. Will we see protection or reinfection in COVID-19?
32303696 ä. Macrophages: a Trojan horse in COVID-19?
32353251 ä. COVID-19 cytokine storm: the interplay between inflammation and coagulation
32339596 ä. Predictive factors of poor outcomes in the COVID-19 epidemic: Consider the inflammatory response
32249847 ä. In the eye of the COVID-19 cytokine storm
32307254 ä. Invasive fungal diseases during COVID-19: We should be prepared
32297939 ä. SARS-CoV-2 and Legionella Co-infection in a Person Returning from a Nile Cruise
32293646 ä. Rates of Co-infection Between SARS-CoV-2 and Other Respiratory Pathogens
32330428 ä. Hospital-based use of thromboprophylaxis in patients with COVID-19
32268022 ä. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19
32294340 ä. Immune Thrombocytopenic Purpura in a Patient with Covid-19
32334650 ä. Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes
32360126 2020. Myocardial injury and COVID-19: Possible mechanisms
32302081 ä. ST-Segment Elevation in Patients with Covid-19 ? A Case Series
32319272 2020. COVID-19 and cardiovascular disorder
32340429 2020. The role of natriuretic peptide estimation in severe COVID-19
32348640 ä. Out-of-Hospital Cardiac Arrest during the Covid-19 Outbreak in Italy
32139904 ä. COVID-19 and the cardiovascular system
32305563 ä. Features of anosmia in COVID-19
32302082 ä. Guillain-Barre Syndrome Associated with SARS-CoV-2
32294339 ä. Neurologic Features in Severe SARS-CoV-2 Infection
32336473 ä. COVID-19 y aparato digestivo
32240876 2020. Hyperglycemia and the novel Covid-19 infection: Possible pathophysiologic mechanisms
32342369 2020. Wie das Coronavirus den Magen-Darm-Trakt angreift: Seminar / Gastromodul
32273593 ä. Kidney involvement in COVID-19 and rationale for extracorporeal therapies
32243911 ä. C-reactive protein levels in the early stage of COVID-19
32291399 ä. Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies
32249846 ä. Dysregulation of lung myeloid cells in COVID-19
32370951 ä. Missed or Delayed Diagnosis of Kawasaki Disease During the 2019 Novel Coronavirus Disease (COVID-19) Pandemic
32341622 2020. SARS-CoV-2: Camazotz s Curse
32246819 2020. Pulmonary High-Resolution Computed Tomography (HRCT) Findings of Patients with Early-Stage Coronavirus Disease 2019 (COVID-19) in Hangzhou, China
32358574 ä. 100 years of influenza research seen through the lens of Covid-19
32333644 2020. RT-LAMP for rapid diagnosis of coronavirus SARS-CoV-2
32183357 2020. 2019 Novel Coronavirus Disease (COVID-19): Paving the Road for Rapid Detection and Point-of-Care Diagnostics
32106462 2020. Disposable DNA Amplification Chips with Integrated Low-Cost Heaters ?
32074444 2020. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients
32367213 ä. CT-Verlauf einer Coronavirus(2019-nCoV)-Pneumonie
32358406 2020. COVID-19 with cystic features on computed tomography: A case report
32344326 2020. COVID-19 and malaria: A symptom screening challenge for malaria endemic countries
32336080 2020. Extracorporeal membrane oxygenation for critically ill patients with coronavirus-associated disease 2019: an updated perspective of the European experience
32236089 2020. Respiratory physiotherapy in patients with COVID-19 infection in acute setting: a Position Paper of the Italian Association of Respiratory Physiotherapists (ARIR)
32268719 2020. Intubation and mechanical ventilation of patients with COVID-19: what should we tell them?
32333196 2020. Lymphopenia that may develop in patients treated with temozolomide and immune control check-point inhibitor may be a high risk for mortality during the COVID-19 outbreak
32271125 2020. Diabetes and the COVID-19 Pandemic: How Insights from Recent Experience Might Guide Future Management
32220612 2020. Diabetes patients with COVID-19 need better blood glucose management in Wuhan, China
32220611 2020. Commentary: COVID-19 in patients with diabetes
32275971 ä. COVID-19 in patients with diabetes: risk factors that increase morbidity
32360211 ä. Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease
32360397 ä. Mechanisms of increased morbidity and mortality of SARS-CoV-2 infection in individuals with diabetes: what this means for an effective management strategy
32353356 ä. Obesity: the ?Achilles heel? for COVID-19?
32333939 2020. Importance of metabolic health in the era of COVID-19
32333938 2020. Obesity hypoventilation syndrome and severe COVID-19
32320741 2020. Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease
32320740 ä. Low-density lipoprotein is a potential predictor of poor prognosis in patients with coronavirus disease 2019
32320742 ä. COVID-19 and diabetes mellitus: what we know, how our patients should be treated now, and what should happen next?
32271728 2020. Coronavirus Disease 2019 in Children - United States, February 12?April 2, 2020
32345328 2020. Analysis of the susceptibility of lung cancer patients to SARS-CoV-2 infection
32218613 ä. Coronaviruserkrankung bei Kindern ? erste Daten aus Wuhan
32317808 ä. COVID-19 bei hospitalisierten Kindern und Jugendlichen: Ein systematischer Review zu publizierten Fallserien (Stand 31 03 2020) und erste Daten aus Deutschland |
32339915 ä. Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19
32315980 2020. COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?
32348641 ä. Covid-19 in Immune-Mediated Inflammatory Diseases ? Case Series from New York
32187458 ä. SARS-CoV-2 Infection in Children
32163697 2020. Detection of Covid-19 in Children in Early January 2020 in Wuhan, China
32227760 ä. Renin?Angiotensin?Aldosterone System Inhibitors in Patients with Covid-19
32302077 ä. Clinical Characteristics of Pregnant Women with Covid-19 in Wuhan, China
32237670 ä. An Uncomplicated Delivery in a Patient with Covid-19 in the United States
32265531 ä. COVID-19 and cancer: what we know so far
32346090 ä. Does asthma make COVID-19 worse?
32246101 ä. Controversies of renin?angiotensin system inhibition during the COVID-19 pandemic
32219356 ä. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)
32369030 2020. Considerations for Postacute Rehabilitation for Survivors of COVID-19
32333842 2020. The key role of palliative care in response to the COVID-19 tsunami of suffering
32197096 ä. COVID-19 in pregnant women ? Authors reply
32283004 ä. Universal Screening for SARS-CoV-2 in Women Admitted for Delivery
32346676 ä. Crowdsourcing a crisis response for COVID-19 in oncology
32161408 2020. Lack of maternal?fetal SARS-CoV-2 transmission
32284613 ä. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding
32231328 ä. Interaction between RAAS inhibitors and ACE2 in the context of COVID-19
32327737 ä. Obesity and impaired metabolic health in patients with COVID-19
32224310 ä. Clinical and virological data of the first cases of COVID-19 in Europe: a case series
32164830 2020. COVID-19 with spontaneous pneumomediastinum
32229159 ä. SARS-CoV-2 infection presenting with hematochezia
32004427 2020. First Case of 2019 Novel Coronavirus in the United States
32220650 ä. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study
32087116 2020. Asymptomatic cases in a family cluster with SARS-CoV-2 infection
32105632 ä. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study
32379729 2020. Characteristics and Clinical Outcomes of Adult Patients Hospitalized with COVID-19 - Georgia, March 2020
32214079 2020. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) - United States, February 12-March 16, 2020
32290644 2020. Clinical and epidemiologic profile of the initial COVID-19 patients at a tertiary care centre in India
32227758 ä. Covid-19 in Critically Ill Patients in the Seattle Region ? Case Series
32302078 ä. Clinical Characteristics of Covid-19 in New York City
32305438 ä. The AAD COVID-19 Registry: Crowdsourcing Dermatology in the Age of COVID-19
32309814 ä. Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries
32290293 2020. A Review of SARS-CoV-2 and the Ongoing Clinical Trials
32363333 ä. A real-time dashboard of clinical trials for COVID-19
C7158785 ä. Convalescent plasma: A possible treatment of COVID-19 in India
32217166 2020. Chloroquine and COVID-19, where do we stand??
32240719 ä. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection
32353355 ä. Testosterone, a key hormone in the context of COVID-19 pandemic
32344177 2020. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect
32305500 ä. Chloroquine paradox may cause more damage than help fight COVID-19
32370766 2020. Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines
32307014 2020. Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19
32255312 2020. A possible probiotic (S salivarius K12) approach to improve oral and lung microbiotas and raise defenses against SARS-CoV-2
32365556 2020. Pharmacological (or Synthetic) and Nutritional Agonists of PPAR-gamma as Candidates for Cytokine Storm Modulation in COVID-19 Disease
32316270 2020. COVID-19, Chloroquine Repurposing, and Cardiac Safety Concern: Chirality Might Help
32231349 2020. Chloroquine in COVID-19: the evidence
32231348 2020. Emerging prophylaxis strategies against COVID-19
32291351 2020. Repurposing Didanosine as a Potential Treatment for COVID-19 Using Single-Cell RNA Sequencing Data
32187464 ä. A Trial of Lopinavir?Ritonavir in Adults Hospitalized with Severe Covid-19
32187463 ä. Covid-19 ? The Search for Effective Therapy
32275812 ä. Compassionate Use of Remdesivir for Patients with Severe Covid-19
32354113 2020. On Facing the SARS-CoV-2 (COVID-19) with Combination of Nanomaterials and Medicine: Possible Strategies and First Challenges
32326343 2020. Can Nanotechnology and Materials Science Help the Fight against SARS-CoV-2?
32366817 2020. A human monoclonal antibody blocking SARS-CoV-2 infection
32203437 ä. Insights from nanomedicine into chloroquine efficacy against COVID-19
32358580 ä. COVID-19: a case for inhibiting IL-17?
32358579 ä. Will helminth co-infection modulate COVID-19 severity in endemic regions?
32296135 ä. COVID-19: risk for cytokine targeting in chronic inflammatory diseases?
32355330 ä. Inactivated vaccine for SARS-CoV-2
32327719 ä. Complement as a target in COVID-19?
32346092 ä. Cancer therapy tool informs COVID-19 vaccines
32346094 ä. COVID-19 vaccine design: the Janus face of immune enhancement
32317716 ä. The potential danger of suboptimal antibody responses in COVID-19
32286538 ä. Human antibodies can neutralize SARS-CoV-2
32303482 ä. Re-emergence of SARS-CoV2 in a discharged COVID-19 case
32299784 ä. How do we decide to de-isolate COVID-19 patients?
32105304 2020. Positive RT-PCR Test Results in Patients Recovered From COVID-19
32276848 ä. Prolonged viral shedding in feces of pediatric patients with coronavirus disease 2019
32224116 ä. Do children need a longer time to shed SARS-CoV-2 in stool than adults?
32035510 2020. 2019-nCoV transmission through the ocular surface must not be ignored
32199469 2020. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples
32214231 ä. COVID-19: faecal?oral transmission?
32340347 2020. Airborne Transmission Route of COVID-19: Why 2 Meters/6 Feet of Inter-Personal Distance Could Not Be Enough
32360356 ä. Putting some context to the aerosolization debate around SARS-CoV-2
32294374 ä. Droplets and Aerosols in the Transmission of SARS-CoV-2
32129805 2020. Air, Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic Patient
32203710 2020. Rational use of face masks in the COVID-19 pandemic
32344688 2020. 3-D Printed Protective Equipment during COVID-19 Pandemic
32322988 ä. Umgang mit COVID-19 in der Notaufnahme: Erfahrungsbericht der interdisziplinären Notaufnahme des Universitätsklinikums Münster
32329322 2020. In considerations of robotic colorectal surgery within a COVID-19 pandemic
32327626 2020. Management of inflammatory bowel disease during COVID-19 pandemic
32225135 2020. Pathways for urology patients during the COVID-19 pandemic
32202401 2020. Urology practice during COVID-19 pandemic
32253371 2020. Impact of the COVID-19 pandemic on urology residency training in Italy
32368875 2020. Guide for Nuclear Medicine Applications During the COVID-19 Outbreak
32210421 2020. COVID-19 in intensive care Some necessary steps for health care workers
32297490 2020. COVID-19 pandemic: what consequences for cardiac rehabilitation?
32278860 2020. Immunosuppression during the COVID-19 pandemic in neuromyelitis optica spectrum disorders patients: A new challenge
32335508 2020. One Aspect of Coronavirus disease (COVID-19) Outbreak in Iran: High Anxiety among MS Patients
32334820 2020. The COVID-19 pandemic and the use of MS disease-modifying therapies
31986242 2020. Medical Journals and the 2019-nCoV Outbreak
32329975 ä. Covid-19 and Kidney Transplantation
32242095 ä. Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic
32341524 ä. Cancer and COVID-19 ? potentially deleterious effects of delaying radiotherapy
32296166 ä. Provision of cancer care during the COVID-19 pandemic
32214232 ä. Management of IBD during the COVID-19 outbreak: resetting clinical priorities
32249840 ä. Minimizing the risk of COVID-19 among patients on dialysis
32035030 2020. The mental health of medical workers in Wuhan, China dealing with the 2019 novel coronavirus
32085839 2020. Mental health care for medical staff in China during the COVID-19 outbreak
32291383 2020. Psychological Impact and Coping Strategies of Frontline Medical Staff in Hunan Between January and March 2020 During the Outbreak of Coronavirus Disease 2019 (COVID-19) in Hubei, China
32294078 2020. Comparison of the Indicators of Psychological Stress in the Population of Hubei Province and Non-Endemic Provinces in China During Two Weeks During the Coronavirus Disease 2019 (COVID-19) Outbreak in February 2020
32283124 ä. Reduction in ST-Segment Elevation Cardiac Catheterization Laboratory Activations in the United States during COVID-19 Pandemic
32305069 ä. Protecting workers aged 60?69 years from COVID-19
32219471 ä. Mutterschutz ? auch im Zeitalter der Coronakrise
32242087 ä. What the stock market tells us about the post-COVID-19 world
32236594 2020. Possibility of transmission through dogs being a contributing factor to the extreme Covid-19 outbreak in North Italy
31996413 2020. Discovery of Bat Coronaviruses through Surveillance and Probe Capture-Based Next-Generation Sequencing
32051570 2020. Novel coronavirus takes flight from bats?
32376697 2020. An Extensive Meta-Metagenomic Search Identifies SARS-CoV-2-Homologous Sequences in Pangolin Lung Viromes
32284615 ä. The proximal origin of SARS-CoV-2
32282789 2020. Public Health Interventions to Mitigate Early Spread of SARS-CoV-2 in Poland
32244041 2020. Shell disorder analysis predicts greater resilience of the SARS-CoV-2 (COVID-19) outside the body and in body fluids
32088333 2020. Lessons learned from the 2019-nCoV epidemic on prevention of future infectious diseases
32087334 2020. The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future
32278074 ä. Emergency response to the outbreak of COVID-19: the Korean case
32379733 2020. Public Health Response to the Initiation and Spread of Pandemic COVID-19 in the United States, February 24-April 21, 2020
32379731 2020. COVID-19 Among Workers in Meat and Poultry Processing Facilities - 19 States, April 2020
32352957 2020. Assessment of SARS-CoV-2 Infection Prevalence in Homeless Shelters - Four U S Cities, March 27-April 15, 2020
32134909 2020. Active Monitoring of Persons Exposed to Patients with Confirmed COVID-19 - United States, January-February 2020
32324720 2020. Cleaning and Disinfectant Chemical Exposures and Temporal Associations with COVID-19 ? National Poison Data System, United States, January 1, 2020?March 31, 2020
32298247 2020. Characteristics of Health Care Personnel with COVID-19 - United States, February 12-April 9, 2020
32265315 2020. 2019 Novel Coronavirus (COVID-19) Pandemic: Built Environment Considerations To Reduce Transmission
32003551 2020. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany
31995857 2020. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus?Infected Pneumonia
32329972 ä. Asymptomatic Transmission, the Achilles? Heel of Current Strategies to Control Covid-19
32182409 ä. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1
32289214 ä. Spread of SARS-CoV-2 in the Icelandic Population
32273611 ä. A framework for identifying regional outbreak and spread of COVID-19 from one-minute population-wide surveys
31988464 2020. China s response to a novel coronavirus stands in stark contrast to the 2002 SARS outbreak response
32284619 ä. On the responsible use of digital data to tackle the COVID-19 pandemic
32284618 ä. Digital technology and COVID-19
32322102 ä. Modelling the COVID-19 epidemic and implementation of population-wide interventions in Italy
32221514 ä. How behavioural science data helps mitigate the COVID-19 crisis
32203324 ä. COVID-19 and the crisis of national development
32294342 ä. Death from Covid-19 of 23 Health Care Workers in China
32334040 ä. The fate of house cats during the COVID-19 pandemic
C7110433 ä. Coronaviren: von der banalen Erkältung zum schweren Lungenversagen: Chronologie einer Pandemie
32108160 2020. Emergence of a novel human coronavirus threatening human health
31988490 2020. Outbreak of a novel coronavirus
32203708 ä. COVID-19 outbreak: less stethoscope, more ultrasound
32192583 2020. COVID-19: delay, mitigate, and communicate
32344311 2020. 2019-nCoV-SARS-CoV-2 (COVID-19) infection: Cruc?al?ty of Fur?n and relevance w?th cancer
32360951 2020. The first Ramadan during COVID-19 pandemic: 1 8 billion Muslims should fast or not?
32368884 2020. Management of COVID-19: the risks associated with treatment are clear, but the benefits remain uncertain
C7144332 ä. On being human in the face of a pandemic
C7118609 ä. NetNCSP: Nonoverlapping closed sequential pattern mining
32365567 2020. Lab-on-a-Chip Technologies for the Single Cell Level: Separation, Analysis, and Diagnostics
- [[PrePrint scene
- prelights
- from the ads
- [lifechemicals.com antiviral candidate drugs]
- [biomol.com assays cytokines general spectrum]
- [labospace.com custom single probe assay 400 possible cytokines and so on]
- [codexdna.com dna synthesis]
- [eclipsebio.com around rna]